BriaCell Therapeutics shares are trading higher after the company announced US FDA authorization of an expanded access policy (EAP) for metastatic breast cancer patients.
Portfolio Pulse from Benzinga Newsdesk
BriaCell Therapeutics shares rose following the US FDA's authorization of an expanded access policy for metastatic breast cancer patients.
September 18, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BriaCell Therapeutics' stock is trading higher due to the US FDA's approval of an expanded access policy for metastatic breast cancer patients, indicating positive regulatory progress.
The FDA's authorization of an expanded access policy is a significant regulatory milestone for BriaCell, likely boosting investor confidence and driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100